A live-attenuated influenza B delNS viral vector vaccine encoding HPV16 E6/E7, administered intratumorally then intramuscularly to induce robust HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses via heightened type I interferon signaling and dendritic cell activation, promoting MHC I–restricted tumor cell killing.
Live-attenuated influenza B delNS viral vector encoding HPV16 E6/E7 delivered intratumorally then intramuscularly to drive strong innate sensing and type I interferon, activate dendritic cells and antigen presentation, and prime HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses, resulting in MHC I–restricted cytotoxic killing of HPV16-positive tumor cells.
YES
INDIRECT
The vaccine induces HPV16 E6/E7–specific CD8+ T cells that recognize E6 peptides on MHC I and kill tumor cells via CTL mechanisms (perforin/granzyme, Fas–FasL).
A live-attenuated influenza B delNS viral vector vaccine encoding HPV16 E6/E7, administered intratumorally then intramuscularly to induce robust HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses via heightened type I interferon signaling and dendritic cell activation, promoting MHC I–restricted tumor cell killing.
Live-attenuated influenza B delNS viral vector encoding HPV16 E6/E7 delivered intratumorally then intramuscularly to drive strong innate sensing and type I interferon, activate dendritic cells and antigen presentation, and prime HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses, resulting in MHC I–restricted cytotoxic killing of HPV16-positive tumor cells.
YES
INDIRECT
Vaccine primes HPV16 E7–specific CD8+ T cells; tumor cells presenting E7 peptides on MHC I are recognized and lysed by CTLs via perforin/granzyme.
A live-attenuated influenza B delNS viral vector vaccine encoding HPV16 E6/E7, administered intratumorally then intramuscularly to induce robust HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses via heightened type I interferon signaling and dendritic cell activation, promoting MHC I–restricted tumor cell killing.
Live-attenuated influenza B delNS viral vector encoding HPV16 E6/E7 delivered intratumorally then intramuscularly to drive strong innate sensing and type I interferon, activate dendritic cells and antigen presentation, and prime HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses, resulting in MHC I–restricted cytotoxic killing of HPV16-positive tumor cells.
NO
INDIRECT
RIG-I activation by the delNS influenza vector boosts type I IFN and antigen presentation, but killing is mediated by HPV16 E6/E7-specific CD8+ T cells that lyse HPV16-positive tumor cells via MHC I; RIG-I-expressing cells are not specifically targeted.
A live-attenuated influenza B delNS viral vector vaccine encoding HPV16 E6/E7, administered intratumorally then intramuscularly to induce robust HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses via heightened type I interferon signaling and dendritic cell activation, promoting MHC I–restricted tumor cell killing.
Live-attenuated influenza B delNS viral vector encoding HPV16 E6/E7 delivered intratumorally then intramuscularly to drive strong innate sensing and type I interferon, activate dendritic cells and antigen presentation, and prime HPV16 E6/E7–specific CD8+ and CD4+ T-cell responses, resulting in MHC I–restricted cytotoxic killing of HPV16-positive tumor cells.
NO
INDIRECT
The vaccine stimulates innate sensing (including via TLR7) to induce type I IFN and dendritic cell activation, priming HPV16 E6/E7–specific CD8+ T cells that kill HPV16-positive tumor cells via MHC I recognition; TLR7-expressing cells are not targeted for cytotoxic killing.
TROP2-targeting antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to TROP2-expressing tumor cells.
TROP2-targeting monoclonal antibody linked via a cleavable linker to a topoisomerase I inhibitor payload. Binding to TROP2 on tumor cells triggers internalization and intracellular release of the payload, which inhibits topoisomerase I to induce DNA damage and replication stress, leading to apoptosis, with potential bystander killing of adjacent tumor cells.
YES
DIRECT
The anti-TROP2 ADC binds TROP2, is internalized, and releases a topoisomerase I inhibitor that induces DNA damage and apoptosis, with possible bystander killing.